High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

The proto-oncogene EVI1 encodes a DNA binding protein and is located on chromosome 3q26. The gene is aberrantly expressed in acute myeloid leukemia (AML) patients carrying 3q26 abnormalities. Two mRNAs are transcribed from this locus: EVI1 and a fusion of EVI1 with MDS1 (MDS1-EVI1), a gene located 5' of EVI1. The purpose of this study was to investigate which of the 2 gene products is involved in transformation in human AML. To discriminate between EVI1 and MDS1-EVI1 transcripts, distinct real-time quantitative polymerase chain reaction (PCR) assays were developed. Patients with 3q26 abnormalities often showed high EVI1 and MDS1-EVI1 expression. In a cohort of 319 AML patients, 4 subgroups could be distinguished: EVI1(+) and MDS1-EVI1(-) (6 patients; group I), EVI1(+) and MDS1-EVI1(+) (26 patients; group II), EVI1(-) and MDS1-EVI1(+) (12 patients; group III), and EVI1(-) and MDS1-EVI1(-) (275 patients; group IV). The only 4 patients with a 3q26 aberration belonged to groups I and II. Interestingly, high EVI1 and not MDS1-EVI1 expression was associated with unfavorable karyotypes (eg, -7/7q-) or complex karyotypes. Moreover, a significant correlation was observed between EVI1 expression and 11q23 aberrations (mixed lineage leukemia [MLL] gene involvement). Patients from groups I and II had significantly shorter overall and event-free survival than patients in groups III and IV. Our data demonstrate that high EVI1 expression is an independent poor prognostic marker within the intermediate- risk karyotypic group.

[1]  C. Niemeyer,et al.  Expression of the Evi‐1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors , 1997, British journal of haematology.

[2]  M. Ferrò,et al.  Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy , 1985, Cancer.

[3]  N. Copeland,et al.  Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines , 1988, Cell.

[4]  A. Bøyum,et al.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968 .

[5]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[6]  U. Jaeger,et al.  Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26) , 2000, Annals of Hematology.

[7]  J. Rowley,et al.  Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia , 1985 .

[8]  A. Biondi,et al.  EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML) , 1997, Leukemia.

[9]  J. Rowley,et al.  11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Touw,et al.  Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells. , 1986, Blood.

[11]  R. Gascoyne,et al.  Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3 , 1993, British journal of haematology.

[12]  S. Orkin,et al.  Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Harris,et al.  Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. , 1992, Nucleic acids research.

[14]  P. Greenberg,et al.  Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. , 1994, Blood.

[15]  K. Horibe,et al.  Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. , 1999, Medical and pediatric oncology.

[16]  K. Sano,et al.  Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1 , 2001, Leukemia.

[17]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[18]  G. Nucifora.  The EVI1 gene in myeloid leukemia , 1997, Leukemia.

[19]  A. Böyum.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[20]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.

[21]  N. Kamada,et al.  Abnormal expression of Evi-1 gene in human leukemias. , 1996, Human cell.

[22]  J. Ihle,et al.  The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. , 1990, Oncogene.

[23]  J. Ihle,et al.  Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Nucifora,et al.  The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator , 1997, Leukemia.

[25]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[26]  V. Ribrag,et al.  Expression of the Evi-1 gene in myelodysplastic syndromes. , 1995, Leukemia.

[27]  R. Sood,et al.  Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements , 1999, Leukemia.

[28]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[29]  L. Wagner,et al.  Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia , 1997, Leukemia.

[30]  M. Witt,et al.  The EVI-1 gene--its role in pathogenesis of human leukemias. , 2000, Leukemia research.

[31]  N. Zeleznik-Le,et al.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. , 1996, Blood.

[32]  R. Taetle,et al.  Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. , 1993, Leukemia.

[33]  S. Nakazawa,et al.  Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. , 1995, Blood.

[34]  J. Rowley,et al.  Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Mitelman.  ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .

[36]  B. Bain,et al.  EVI1 expression in acute myeloid leukaemia , 2001, British journal of haematology.

[37]  W. V. Putten,et al.  Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene , 2001, Leukemia.